Previous 10 | Next 10 |
AtriCure Inc. (ATRC) Q1 2022 Results Conference Call May 3, 2022 04:30 PM ET Company Participants Marissa Bych - Gilmartin Group Michael Carrel - President, CEO Angela Wirick - CFO Conference Call Participants Robbie Marcus - JPMorgan Danielle Antalffy - SVB Leerink John McAulay - Stifel Sam ...
AtriCure press release (NASDAQ:ATRC): Q1 Non-GAAP EPS of -$0.33 beats by $0.01. Revenue of $74.58M beats by $3.41M. For FY22 revenue is projected to be ~$318M-330M, Non-GAAP EPS of ~$1.07-1.12 For further details see: AtriCure Non-GAAP EPS of -$0.33 beats by $0.01, revenue of $74.58M be...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results. “Our team deliver...
New clamp is designed to improve efficiency of concomitant ablation procedures AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, t...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2022 financial results on ...
AtriCure Inc. (ATRC) Q4 2021 Results Conference Call February 15, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group Michael Carrel - President, CEO Angela Wirick - CFO Conference Call Participants David Saxon - Needham Robbie Marcus - JPMorgan Matthew O'Brien - Piper Sandler...
AtriCure press release (NASDAQ:ATRC): Q4 Non-GAAP EPS of -$0.30 beats by $0.01. Revenue of $73.22M (+26.8% Y/Y) beats by $0.56M. For further details see: AtriCure Non-GAAP EPS of -$0.30 beats by $0.01, revenue of $73.22M beats by $0.56M
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2021 and full year 2021 financial results. ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today published its inaugural Environmental, Social and Governance (ESG) report hi...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 11 th Annual SVB Leerink Global Healthcare Conference...
News, Short Squeeze, Breakout and More Instantly...
2024-07-31 08:00:12 ET Rick Wise from Stifel Nicolaus issued a price target of $26.00 for ATRC on 2024-07-31 06:57:00. The adjusted price target was set to $26.00. At the time of the announcement, ATRC was trading at $22. The overall price target consensus is at $56.00 w...
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), l...
CFSB Bancorp Inc. (CFSB) is expected to report for Q4 2024 Big 5 Sporting Goods Corporation (BGFV) is expected to report $-0.48 for Q2 2024 Canadian Pacific Kansas City Limited (CP) is expected to report $0.74 for Q2 2024 Captivision Inc. (CAPT) is expected to report for quarter end 2...